← Eichor
Study identifier: NCT07146295 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Implementation of Indocyanine Green to Identify Sentinel Lymph Nodes During Surgery for Breast Cancer

Condition: Breast Cancer · Sentinel Lymph Node Biopsy (SLNB) · Sentinel Lymph Node Detection  ·  Sponsor: Isabelle Henskens

PhaseNA
Planned participants1760
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to learn how to successfully introduce a new method for finding the sentinel lymph node during breast cancer surgery into routine hospital care. The method uses a dye called indocyanine green (ICG) and a special camera to see the lymph node. The sentinel lymph node is the first lymph node that cancer is likely to spread to. In the Netherlands, about 1 in 7 women develops breast cancer. Finding out whether cancer has spread to the lymph nodes is important for planning treatment and predicting outcomes. The current standard method for sentinel lymph node biopsy (SLNB) uses a radioactive tracer called radioisotope technetium-labeled (99mTc)-nanocolloid. While accurate, this method has several drawbacks: it exposes patients to radioactivity, requires an extra hospital visit or travel to another hospital due to limited nuclear medicine facilities, and is not sustainable. Surgeries using 99mTc can only take place on certain days due to logistical issues, and the signal from 99mTc can be disturbed by the tumor marker placed in the breast. ICG works as well as 99mTc for SLNB and offers several advantages: it is given during surgery (no extra visit needed), produces no radiation, and reduces costs. However, it is still not widely used in the Netherlands because hospitals may not be familiar with it or unsure how to make the switch. This study will introduce ICG step-by-step in several Dutch hospitals and evaluate how to make the change as smooth a…

This description comes directly from the study's public registry record.

Talk to the study team

Isabelle Henskens, MD  ·  +31883202902  ·  i.henskens@antoniusziekenhuis.nl

Annemiek Doeksen, MD, PhD  ·  +3188 320 29 00.  ·  a.doeksen@antoniusziekenhuis.nl

Always discuss trial participation with your own doctor first.

Locations (7)

Noordwest ZiekenhuisgroepAlkmaar, NetherlandsRecruiting
Ziekenhuisgroep TwenteHengelo, NetherlandsRecruiting
Spaarne GasthuisHoofddorp, NetherlandsRecruiting
Dijklander ZiekenhuisHoorn, NetherlandsRecruiting
Alrijne HospitalLeiden, NetherlandsRecruiting
Canisius Wilhelmina ZiekenhuisNijmegen, NetherlandsRecruiting
DiakonessenhuisUtrecht, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07146295